Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results

Journal of Clinical Oncology

Volumn 23, Issue 27, 2005, Pages 6763-6770

  Liersch, Torsten ^a   Meller, Johannes ^a   Kulle, Bettina ^a   Behr, Thomas M ^a   Markus, Peter ^a   Langer, Claus ^a   Ghadimi, B Michael ^a   Wegener, William A ^a   Kovacs, Jacqueline ^a   Horak, Ivan D ^a   Becker, Heinz ^a   Goldenberg, David M ^a  

^a IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LABETUZUMAB I 131; MONOCLONAL ANTIBODY; OXALIPLATIN; UNCLASSIFIED DRUG; RADIOACTIVE IODINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; SINGLE DRUG DOSE; THROMBOCYTOPENIA; ADENOCARCINOMA; CANCER STAGING; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; RADIATION RESPONSE; RISK ASSESSMENT; SURVIVAL; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; BIOPSY, NEEDLE; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOIMMUNOTHERAPY; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 27244458791     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.18.622     Document Type: Article

References (33)

1. DeVita VT, Hellman S, Rosenberg SA Cancer: Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott Raven, 1997
2. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
3. Blumgart LH, Fong Y: Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg 32:333-421, 1995
4. Doci R, Gennari L, Bignami P, et al: One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants. Br J Surg 78:797-801, 1991
5. Wagner JS, Adson MA, van Heerden JA, et al: The natural history of hepatic metastases from colorectal cancer. Ann Surg 199:502-508, 1984
6. Lehnert T, Otto G, Herfarth C: Therapeutic modalities and prognostic factors for primary and secondary liver tumors. World J Surg 19:252-263, 1995
7. Geoghegen JG, Scheele J: Treatment of colorectal liver metastases. Br J Surg 86:158-169, 1999
8. Doci R, Gennari L, Bignami P, et al:. Morbidity and mortality after hepatic resection of metastases from colorectal cancer. Br J Surg 82:377-381, 1995
9. Fong Y: Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 49:231-255, 1999
10. Hughes K, Scheele J, Sugarbaker PH: Surgery for colorectal cancer metastatic to the liver: Optimizing the results of treatment. Surg Clin North Am 69:339-359, 1989
11. Fortner JG: Recurrence of colorectal cancer after hepatic resection. Am J Surg 155:378-382, 1988
12. Gold P, Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122:467-481, 1965
13. Gold P, Goldenberg NA: The carcinoembryonic antigen (CEA): Past, present, and future. McGill J Med 3:46-66, 1997
14. Sharkey RM, Weadock KS, Natale A, et al: Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst 83:627-632, 1991
15. Behr TM, Blumenthal RD, Memtsoudis S, et al: Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res 6:4900-4907, 2000
16. Behr TM, Salib AL, Liersch T, et al: Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. Clin Cancer Res 5:3232s-3242s, 1999
17. Hansen HJ, Goldenberg DM, Newman ES, et al: Characterization of second generation monoclonal antibodies against carcinoembryonic antigen. Cancer 71:3478-3485, 1993
18. Hajjar G, Sharkey RM, Burton J, et al: Phase I radioimmunotherapy trial with iodine-131-labelled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2:31-42, 2002
19. Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693-713, 2002
20. Dunn RM, Juweid M, Sharkey RM, et al: Can occult metastases be treated by radioimmunotherapy? Cancer 80:2656-2659, 1994 (suppl)
21. Gayowski TJ, Iwatsuki S, Madariaga JR, et al: Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors. Surgery 116:703-710, 1994
22. Sobin LH, Wittekind C UICC: TNM Classification of Malignant Tumors (ed 5). New York, NY, John Wiley & Sons, 1997
23. Jaeck D, Bachellier P, Guiguet M, et al: Long-term survival following resection of colorectal hepatic metastases: Association Francaise de Chirurgie. Br J Surg 84:977-980, 1997
24. Nordlinger B, Guiguet M, Vaillant JC, et al: Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients-Association Francoise de Chirurgie. Cancer 77:1254-1262, 1996
25. Bismuth H, Adam R, Lévi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-522, 1996
26. Topal B, Kaufman L, Aerts R, et al: Patterns of failure following curative resection of colorectal liver metastases. Eur J Surg Oncol 29:248-253, 2003
27. Penna C, Nordlinger B: Surgery of liver metastases from colorectal cancer: New promises. Br Med Bull 64:127-140, 2002
28. Lorenz M, Müller HH, Schramm H, et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer: German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228:756-762, 1998
29. Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039-2048, 1999
30. Gill S, Thomas RR, Goldberg RM: New targeted therapies in gastrointestinal cancers. Curr Treat Options Oncol 4:393-403, 2003
31. Hurwitz H: Integrating the anti-VEGF: A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4:S62-S68, 2004 (suppl 2)
32. Koppe MJ, Soede AC, Pels W, et al: Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. Int J Cancer 106:965-972, 2003
33. Blumenthal RD, Osorio L, Hayes MK, et al: Carcinoembryonic antigen antibody inhibits metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother 54:315-327, 2005